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S U M M A R Y
Background: Skin and soft tissue infections (SSTIs) are among the most common infectious diseases and a
frequent cause of hospital visits. In this study we sought to assess the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) and antibiotic susceptibility patterns in SSTIs in patients attending
hospitals in Kenya.
Methods: Eighty-two S. aureus isolates recovered from SSTIs from both inpatients and outpatients were
screened for antibiotic susceptibility, possession of staphylococcal cassette chromosome mec (SCCmec)
gene type, and the Panton–Valentine leukocidin (PVL) toxin gene. The prevalence of MRSA was
investigated in relation to the type of patient and infection type, as well as the type of health care facility.
Results: Of 60 boil cultures, 39 (65%) grew S. aureus, of out of which 34 (87.2%) were MRSA. Of the 60
abscess cultures, 14 (23.3%) grew S. aureus, of which 10 (71.4%) were MRSA. Of 34 cellulitis cultures, 18
(52.9%) grew S. aureus, of which 16 (88.8%) were MRSA. Of 25 ulcer cultures, 11 (44%) grew S. aureus, of
which nine (81.8%) were MRSA. Sixty-nine of 82 S. aureus (84.1%) were MRSA, with 52 (75.4%) possessing
SCCmec II type and 14 (20.3%) being positive for the PVL gene. Based on hospitals, it was noted that most
MRSA were isolated at publicly funded health care facilities serving an economically disadvantaged
segment of Nairobi’s population, such as those living in urban informal settlements. All 82 S. aureus were
susceptible to vancomycin and resistant in high numbers to macrolides, aminoglycosides, and
quinolones. Bacterial isolates were mostly susceptible to vancomycin, ciproﬂoxacin and co-trimoxazole,
and none was resistant to vancomycin. However, most organisms showed decreased susceptibility to
erythromycin and clindamycin.
Conclusions: These ﬁndings suggest that SCCmec II MRSA and a PVL strain of MRSA are signiﬁcant
pathogens in patients with SSTIs presenting to hospitals in Kenya, and that MRSA cases are prevalent at
publicly funded health care facilities.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococcus aureus is a major pathogen responsible for
various infections including bacteremia, pneumonia, skin and soft
tissue infections (SSTIs), and osteomyelitis.1,2 Over the past 50
years S. aureus has acquired resistance to previously effective
antimicrobials including the penicillinase-resistant ones like
methicillin.2 Today, methicillin-resistant S. aureus (MRSA) poses
a serious therapeutic problem worldwide.3,4 The percentage of
hospitals isolating MRSA in the developed countries increased
from 2% in the 1970s to 30% in the 1990s.4,5 Although MRSA is a
serious global pathogen, studies are largely skewed to afﬂuent* Corresponding author.
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1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.09.006regions and as such there is very little information regarding the
frequency and characteristics of MRSA in developing countries,
especially in Africa.
Carriage of MRSA by healthcare workers has been studied
extensively with respect to the role that this may play in spreading
MRSA to patients. A study published in 2009 found the prevalence
of MRSA in doctors and nurses working in the intensive care units
and surgical units in six hospitals in Tripoli, Libya to be 36.8%. In
Africa, data on MRSA, particularly antibiotic susceptibilities, are
extremely limited and the magnitude of the problem is yet to be
quantiﬁed.6–8 A study aimed at determining the prevalence and
antibiotic susceptibility patterns of MRSA in African countries
found relatively high prevalence rates in Nigeria, Kenya, and
Cameroon (21–30%), and below 10% in Tunisia, Malta, and Algeria.8
Surveillance of staphylococcal colonization and cross-infection in
hospitals located in Cape Verde showed an S. aureus carriage rate ofses. Published by Elsevier Ltd. All rights reserved.
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outpatients.9 This observation emphasizes the need to maintain
surveillance and control of MRSA infections in Africa.
This study was an attempt to assess the prevalence of MRSA and
antibiotic susceptibility patterns in SSTIs in patients attending
hospitals in Kenya.
2. Materials and methods
2.1. Study design
This was a prospective study involving a convenience sample of
patients (inpatients and outpatients) who presented with SSTIs to
ﬁve different health facilities in Nairobi, Kenya, during 2005–2007.
The health facilities were categorized as: facility 1: a public tertiary
research center; facilities 2 and 3: private hospitals in Nairobi;
facility 4: a public district hospital; and facility 5: a public tertiary
referral hospital. Written informed consent to participate in this
study was required, and all patients agreed to participate by
signing an informed consent form.
2.2. Inclusion and exclusion criteria
Patients were screened by trained nursing staff or a
treating physician for inclusion/exclusion in the study either
immediately after admission, or during the outpatient visits.
Inclusion criteria for patients were: admission to an inpatient/
outpatient service, presence of an active SSTI as determined by
the treating physician, at least 18 years of age, ability to
understand risks/beneﬁts, and consent to participation in the
study. Patients were excluded if they had an uncomplicated skin
or superﬁcial skin structure infection such as simple skin
abrasion. Patients with necrotizing fasciitis, gas gangrene, and
osteomyelitis were excluded from the study. Children and
those patients who refused to sign the informed consent form
were excluded. SSTIs were deﬁned as cellulitis, skin abscess,
infected skin ulcer, infected surgical incision, infected traumatic
wound, diabetic foot ulcer, decubitus ulcer, ischemic ulcer,
or infected bite. For the latter four diagnoses, the infection
had to involve the soft tissues only, without concomitant
osteomyelitis.
2.3. Bacterial isolates and culture conditions
Culture swabs from SSTIs were immediately streaked onto
mannitol salt and nutrient agar. Plates were incubated at 35 8C for
48 h in aerobic conditions. Colonies demonstrating S. aureus colony
morphology were subcultured onto trypticase soy agar with 5%
deﬁbrinated sheep blood (Nissui Pharmaceutical Co. Ltd) and
incubated overnight at 35 8C. Identiﬁcation of S. aureus was based
on colony morphology on trypticase soy agar supplemented with
5% sheep blood, growth on mannitol salt agar, Gram stain, and a
positive tube coagulase test using rabbit plasma (Oxoid Ltd,
Hampshire, UK).
2.4. Antimicrobial susceptibility testing
Conﬁrmed S. aureus were screened for antibiotic sensitivity
with nine antibiotics by disk diffusion method, as standardized by
the Clinical and Laboratory Standards Institute (CLSI).10 Antibiotics
included methicillin (10 mg), oxacillin (1 mg), cefoxitin (30 mg),
erythromycin (15 mg), gentamicin (10 mg), ciproﬂoxacin (5 mg),
clindamycin (10 mg), co-trimoxazole (25 mg), and vancomycin
(30 mg). All tests were performed on Mueller–Hinton agar (Oxoid
Ltd, Hampshire, UK) and interpreted after incubation at 37 8C
overnight.2.5. Oxacillin, cefoxitin, and inducible clindamycin resistance, and
penicillin binding protein 2a (PBP2a) screening
In addition, all isolates were subjected to oxacillin resistance
screening agar, Mueller–Hinton agar (supplemented with 4% NaCl
containing 6 mg of oxacillin per ml), and cefoxitin disk diffusion
test using 30 mg cefoxitin disks on Mueller–Hinton agar, as
recommended by CLSI guidelines.10 The zone diameters measured
around each disk were interpreted as described previously.10 The
double-disk diffusion D-test with a 2 mg clindamycin disk and a
15 mg erythromycin disk on the Mueller–Hinton agar plate was
used to test for inducible clindamycin resistance. Isolates were
further screened using a PBP20 latex agglutination test kit (Slidex
MRSA detection; Denka Seiken). All MRSA and isolates for which
the PBP2a result was discrepant with the phenotypic result had
their MRSA phenotypes conﬁrmed by testing for mecA, as
previously described.11 S. aureus ATCC 29213 (susceptible to
methicillin) and S. aureus ATCC 43300 (resistant to methicillin)
were used as controls.
2.6. DNA extraction
Total DNA from MRSA isolates was prepared by growing the
strain on 5% sheep blood agar plates for 24 h at 37 8C. One to ﬁve
bacterial colonies were suspended in 50 ml of sterile distilled water
and heated at 99 8C for 10 min. The bacterial suspension was
centrifuged at 30 000  g for 1 min, and 2-ml aliquots of the
supernatant containing total DNA were used for the PCR assays.
2.7. SCCmec typing and PVL gene detection
The nucleotide sequences of mecA primers and their respective
ampliﬁed products have been described previously.11 The primer
sets were designed to anneal to unique regions and to generate
amplicons that would allow identiﬁcation of the mecA gene based
on the molecular mass of its PCR product. As an internal positive
control, S. aureus ATCC 43300 was used. A multiplex PCR
containing six pairs of primers including speciﬁc primers for
SCCmec types I, II, III, IV, and V, and the primer speciﬁc for the mecA
gene (Table 1), was used to determine SCCmec type I–V and mecA
for all MRSA isolates, using methods published previously.11 The
presence of the lukS-PV and lukF-PV genes encoding PVL
components was determined by a PCR-based method with the
primer pair and thermocycler conditions as reported by Lina
et al.12
2.8. PCR conditions and assays
All PCR assays were performed directly from genomic DNA
extracted from cultures grown on agar plates as described
previously.11 Target genes, size, and primers are shown in
Table 1. The SCCmec multiplex PCR typing assay contained six
pairs of primers including the speciﬁc primers for SCCmec types I,
II, III, IV, and V, and the primers for the mecA gene. A 10-ml aliquot
of the PCR product was analyzed in 1.5% agarose gel, and the PCR
products were observed under a UV transilluminator after staining
with 0.5 mg/ml ethidium bromide.
3. Results
3.1. Overall prevalence of bacterial isolates
One hundred and seventy-nine specimens were collected from
100 patients at the ﬁve different health care facilities. Sixty-nine
specimens grew MRSA, 13 grew methicillin-susceptible S. aureus
(MSSA), and 46 grew other bacteria including coagulase-negative
Table 2
Bacterial strains by health care facility and patient type
Facilitya Bacterial isolates Total
MRSA MSSA Other bacteria
Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
F1 32 6 1 1 6 7 53
F2 1 2 2 1 8 12 26
F3 1 2 - - 2 - 5
F4 7 3 4 1 2 1 18
F5 11 4 2 1 2 6 26
Total 52 17 9 4 20 26 128
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
a F1, public tertiary research center; F2 and F3, private hospital in Nairobi; F4, public district hospital; and F5, public tertiary referral hospital.
Table 1
Primers used in the study. The primer sets were designed to anneal to unique regions and to generate amplicons that would allow identiﬁcation of mecA, SCCmec, or PVL genes
based on the molecular mass of their PCR product
Target Primer Oligonucleotide sequence (50–30) Amplicon size (bp) Reference
SCCmec I Type I-F GCTTTAAAGAGTGTCGTTACAGG 613 11
Type I-R GTTCTCTCATAGTATGACGTCC
SCCmec II Type II-F CGTTGAAGATGATGAAGCG 398 11
Type II-R CGAAATCAATGGTTAATGGACC
SCCmec III Type III-F CCATATTGTGTACGATGCG 280 11
Type III-R CCTTAGTTGTCGTAACAGATCG
SCCmec IV Type IV-F GCCTTATTCGAAGAAACCG 776 11
Type IV-R CTACTCTTCTGAAAAGCGTCG
SCCmec V Type V-F GAACATTGTTACTTAAATGAGCG 325 11
Type V-R TGAAAGTTGTACCCTTGACACC
mecA MecA-1 AAA ATC GAT GGT AAA GGT TGG C 533 11
MecA-2 AGT TCT GCA GTA CCG GAT TTG C
PVL luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA 432 12
luk-PV-2 GCATCAASTGTATTGGATAGCAAAAGC
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which were more likely to represent colonization/contamination
than infection. Fifty-one cultures grew yeasts and were not
considered for further screening.
The prevalence of S. aureus at each of the facilities is shown in
Table 2. The prevalence of S. aureus strains in relation to the type of
infection is shown in Figure 1. Most swab cultures were positive for
S. aureus. Of the 60 boil cultures, 39 (65%) grew S. aureus, of which
34 (87.2%) were MRSA. Of the 60 abscess cultures, 14 (23.3%) grew
S. aureus, of which 10 (71.4%) were MRSA. Of 34 cellulitis cultures,
18 (52.9%) grew S. aureus, of which 16 (88.8%) were MRSA. Of 25
ulcer cultures, 11 (44%) grew S. aureus, of which nine (81.8%) were
MRSA.Figure 1. Prevalence of MRSA and MSSA isolation based on clinical presentation.
(Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus; PVL+ MRSA, Panton–Valentine
leukocidin toxin-positive MRSA; PVL MRSA, Panton-Valentine leukocidin toxin-
negative MRSA.).3.2. Antimicrobial sensitivity patterns
Antimicrobial susceptibility data are summarized in Table 3 and
Figure 2. Most isolates were susceptible to vancomycin, ciproﬂox-
acin, and co-trimoxazole, and none was resistant to vancomycin.
However, most organisms showed decreased sensitivity to
gentamicin and erythromycin. Out of 128 isolates, 82 (64.1%)
were S. aureus; 69 (53.9%) were MRSA and 13 (10.2%) were MSSA.
Fifty-one (62.2%) of the S. aureus isolates were erythromycin-
resistant but clindamycin susceptible, out of which 19 (37.2%)
isolates showed inducible clindamycin resistance; 31 (60.8%)
showed constitutive resistance and one (2.0%) isolate was negative
indicating Macrolide-streptogramin type(MS type) (Table 4).
3.3. Analysis of mec and PVL genes
All S. aureus isolates were screened for the mecA gene and those
that were positive were further screened for SCCmec type. AllTable 3
Disk diffusion test for all Staphylococcus aureus isolates to nine antibiotics, on
Mueller–Hinton agar with 4% NaCl, as recommended in the Clinical and Laboratory
Standards Institute guidelines10
Antimicrobial agent Sensitive,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Vancomycin 82 (100) 0 (0) 0 (0)
Methicillin 13 (15.9) 0 (0) 69 (84.1)
Ciproﬂoxacin 21 (25.6) 6 (7.3) 55 (67.1)
Oxacillin 13 (15.9) 0 (0) 69 (84.1)
Cefoxitin 13 (15.9) 0 (0) 69 (84.1)
Co-trimoxazole 20 (24.4) 11 (13.4) 51 (62.2)
Gentamicin 13 (15.9) 0 (0) 69 (84.1)
Erythromycin 15 (18.3) 11 (13.4) 56 (68.3)
Clindamycin 51 (62.2) 0 (0) 31 (37.8)
Figure 2. Sensitivity patterns of Staphylococcus aureus strains to the nine tested
antibiotics. (Abbreviations: VA, vancomycin; MT, methicillin; CP, ciproﬂoxacin; CT,
cefoxitin; OX, oxacillin; SXT, co-trimoxazole; GM, gentamicin; ER, erythromycin;
CD, clindamycin; MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus; PVL+ MRSA, Panton–Valentine
leukocidin toxin-positive MRSA; PVL MRSA, Panton-Valentine leukocidin toxin-
negative MRSA.).
Table 4
Inducible clindamycin resistance test (ICR; D-test) for erythromycin-resistant and
clindamycin-susceptible Staphylococcus aureus. Isolates were tested with a 2 mg
clindamycin disk and a 15 mg erythromycin disk on the Mueller–Hinton agar plate.
Interpretation was based on guidelines provided by the Clinical and Laboratory
Standards Institute10
Isolates Constitutive MLSB
resistance, n (%)
Inducible MLSB
resistance, n (%)
MS phenotype,
n (%)
MRSA (n = 50) 30 (60) 19 (38) 1 (2)
MSSA (n = 1) 0 (0) 0 (0) 1 (100)
Total (n = 51) 31 (60.8) 19 (37.2) 1 (2.0)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; MLSB, macrolide–lincosamide–streptogramin B; MS,.
E.K. Maina et al. / International Journal of Infectious Diseases 17 (2013) e115–e119e118methicillin-, cefoxitin-, oxacillin-, and gentamicin-resistant phe-
notypes carried mecA. Five isolates (7.2%) had SCCmec I, 52 (75.4%)
had SCCmec II, one (1.4%) had SCCmec I and II, and two (2.9%) had
SCCmec IV. No SCCmec III or V was detected, and nine (13.1%)
strains were non-typeable. None of those with the MSSA
phenotype were positive for mecA. The PVL gene was detected
in 14 (20.3%) MRSA isolates and was represented in all clinical
presentations.
4. Discussion
To our knowledge, this is the ﬁrst study to report the prevalence
of MRSA among patients presenting with SSTIs in Kenya. Previous
studies in the region have been limited to speciﬁc departments10,13
and therefore information on the general prevalence of MRSA in
patients has been lacking. Sixty-nine of 82 S. aureus (84.1%)
recovered from SSTIs were MRSA, which is higher than previous
ﬁndings in the region,6,8 suggesting an increase in MRSA
prevalence over the years. This is a wake-up call for health
stakeholders in the region to put into place measures to mitigate
the spread of MRSA. Of the total MRSA, 14 (20.3%) were PVL-
positive and 75.4% possessed SCCmec type II, suggesting that
SCCmec II MRSA and a PVL strain of MRSA are signiﬁcant pathogens
in patients with SSTIs presenting to hospitals in Kenya. Publicly
funded health care facilities had a higher MRSA isolation rate
compared to private hospitals, a ﬁnding consistent with a previous
study in Kenya.14 The prevalence of MRSA in proven staphylococcal
infections in inpatients and outpatients were 75% and 25%,
respectively. These ﬁndings emphasize the need for healthcare
workers to take necessary precautions to avert nosocomial
infections in inpatient departments, as well as the potential
source of MRSA infection in the community. SSTIs are among the
most common infectious diseases and a frequent cause of visits to
healthcare providers. The majority of cultures were positive for S.
aureus, with 87.2% of those from boils, 71.4% from abscesses, and
88.8% from cellulitis being positive for MRSA. These ﬁndings
suggest that MRSA is a signiﬁcant pathogen in these types of
infection.
Antimicrobial susceptibility patterns of the MRSA isolates in
this study are typical of MRSA from other recent reports.2,4,6,8,15,16
Although some strains were susceptible to a number of other non-
b-lactam antibiotics, including ciproﬂoxacin, erythromycin, and
clindamycin, this study demonstrated a reduction in the choice of
antibiotic in the case of MRSA infections. Fortunately all MRSA
isolates in the present study were susceptible to vancomycin. Since
vancomycin is the reserved drug for treating MRSA infections,
these data provide useful information for the healthcare personnel.
Most community-associated MRSA (CA-MRSA) strains carry
SCCmec IV or SCCmec V and are susceptible to most non-b-lactam
antimicrobials, while hospital-associated MRSA (HA-MRSA)strains often carry SCCmec I, II, or III.15 However, some studies
have shown that nosocomial MRSA can carry SCCmec IV.17–19 Two
MRSA isolates in this study were SCCmec IV-positive. The
genotypes of MRSA clone isolates are distinct in different
geographic locations and therefore the genotypes of MRSA clones
in Kenya in relation to other global MRSA clones may not be the
same. We suggest the need for a study to screen for CA-MRSA in
Kenya to provide information on the importance of these strains in
hospitals.
This study clearly demonstrates that MRSA is a signiﬁcant
pathogen in SSTIs and an important cause of wound infections
among the populations at the health facilities covered by this
study. These data provide an insight into the current epidemiology
of MRSA in Kenya and may be important in setting guidelines for
preventing Staphylococcus-related SSTIs in health care facilities.
They are also necessary for drawing up effective therapeutic
guidelines and for S. aureus antibiogram surveillance.
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